Ependymoma Pipeline Analysis Report 2026

Report Coverage

The Ependymoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into ependymoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for ependymoma. The ependymoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The ependymoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with ependymoma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to ependymoma.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Ependymoma Pipeline Outlook

The ependymoma pipeline is progressing through the development of targeted small molecules, monoclonal antibodies, and oncolytic viral therapies, and novel radiotherapeutic approaches designed to improve outcomes in recurrent and treatment-resistant disease. Several investigational candidates are advancing in early- and mid-stage clinical trials, reflecting increasing interest in precision neuro-oncology. In April 2026, the U.S. FDA cleared the IND application for Reyobiq™ (rhenium-186 obisbemeda), enabling the Phase I/II ReSPECT-PBC trial in pediatric patients with recurrent or progressive ependymoma, marking an important milestone in advancing localized radiotherapy for this rare central nervous system tumor.

Ependymoma Epidemiology

Ependymoma is a rare central nervous system tumor, accounting for approximately 1.6%-1.8% of all primary CNS tumors and 6%-12% of pediatric intracranial neoplasms. The annual incidence in the United States is estimated at 0.3-0.4 cases per 100,000 population. Around 90% of pediatric ependymomas occur intracranially, predominantly in the posterior fossa, whereas over 60% of adult cases arise in the spinal cord. The disease is most frequently diagnosed in young children, with a second incidence peak observed in adulthood for spinal ependymomas.

Ependymoma – Pipeline Therapeutic Assessment

Ependymoma Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total ependymoma clinical trials. Early Phase I (3.57%), Phase I (51.43%), Phase II (41.79%), Phase III (3.21%), and Phase IV (0.00%). This phase-wise distribution reflects a strong emphasis on early- and mid-stage clinical development, highlighting continued innovation and the advancement of promising therapeutic candidates for ependymoma.

Ependymoma Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the ependymoma pipeline analysis include small molecules, monoclonal antibodies, and oncolytic viral therapies. The ependymoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ependymoma. In March 2026, Lantern Pharma and Starlight Therapeutics received U.S. FDA clearance for the Investigational New Drug (IND) application of STAR-001, enabling a Phase I pediatric clinical trial in relapsed or refractory central nervous system malignancies, including ependymoma, to evaluate the therapy alone and in combination with spironolactone.

Ependymoma Clinical Trials – Key Players

The EMR report for the ependymoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed ependymoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in ependymoma clinical trials:

• Regeneron Pharmaceuticals
• GlaxoSmithKline
• Cellectar Biosciences, Inc.
• Y-mAbs Therapeutics
• Bristol-Myers Squibb
• CSBio
• The Lilabean Foundation, Inc.
• Takeda
• Incyte Corporation
• Jazz Pharmaceuticals
• First Ascent Biomedical Inc.
• Treovir, Inc.

Ependymoma – Emerging Drugs Profile

Key Questions Answered in the Ependymoma Pipeline Insight Report

• Which companies/institutions are leading the ependymoma drug development?
• Which company is leading the ependymoma pipeline development activities?
• What is the current ependymoma commercial assessment?
• What are the opportunities and challenges present in the ependymoma pipeline landscape?
• What is the efficacy and safety profile of ependymoma pipeline drugs?
• Which company is conducting major trials for ependymoma drugs?
• Which companies/institutions are involved in ependymoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in ependymoma?

Reasons To Buy This Report

The Ependymoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for ependymoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into ependymoma collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Ependymoma Market